Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah L Miller

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
American Journal of Physiology. Endocrinology and Metabolism|November 16, 2017
Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challengeSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Journal of the American Society of Hypertension : JASH|December 7, 2010
Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressureRhonda Kaufman, Irene Nunes, James A Bolognese, et al.
Journal of Clinical Pharmacology|October 22, 2008
Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokineticsJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 14, 2016
Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation seriesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Diabetes|March 17, 2018
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 DiabetesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
BMC Obesity|March 8, 2017
Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetesSudha S Shankar, Lori A Mixson, Manu Chakravarthy, et al.
British Journal of Clinical Pharmacology|September 28, 2012
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteersS Aubrey Stoch, Stefan Zajic, Julie A Stone, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
American Journal of Physiology. Endocrinology and Metabolism|November 16, 2017
Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challengeSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Journal of the American Society of Hypertension : JASH|December 7, 2010
Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressureRhonda Kaufman, Irene Nunes, James A Bolognese, et al.
Journal of Clinical Pharmacology|October 22, 2008
Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokineticsJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 14, 2016
Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation seriesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
Diabetes|March 17, 2018
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 DiabetesSudha S Shankar, R Ravi Shankar, Lori A Mixson, et al.
BMC Obesity|March 8, 2017
Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in subjects with short duration type 2 diabetesSudha S Shankar, Lori A Mixson, Manu Chakravarthy, et al.
British Journal of Clinical Pharmacology|September 28, 2012
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteersS Aubrey Stoch, Stefan Zajic, Julie A Stone, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 2